For many years, placebos have been defi ned by their inert content and their use as controls in clinical trials and treatments in clinical practice. Recent research shows that placebo eff ects are genuine psychobiological events attributable to the overall therapeutic context, and that these eff ects can be robust in both laboratory and clinical settings. There is also evidence that placebo eff ects can exist in clinical practice, even if no placebo is given. Further promotion and integration of laboratory and clinical research will allow advances in the ethical use of placebo mechanisms that are inherent in routine clinical care, and encourage the use of treatments that stimulate placebo eff ects.
Introduction
The notion of something called "placebo" started with St Jerome's mistranslation of the fi rst word of the ninth line of Psalm 116, when instead of translating the Hebrew "I will walk before the Lord", he wrote "Placebo Domino in regione vivorum" ("I will please the Lord in the land of the living"). By the 13th century, when hired mourners waited for Vespers for the Dead to begin, they often chanted the ninth line, and so were called "placebos" to describe their fake behaviour. 1 Later, in The Canterbury Tales, Chaucer named his sycophantic, fl attering courtier Placebo. The introduction of placebo controls, which entailed the administration of fake procedures to separate the eff ects of imagination from reality, began in the 16th century with progressive Catholic eff orts to discredit right-wing exorcisms. 2 Individuals "possessed" by the devil were given false holy objects and if they reacted with violent contortions-as if they were genuine relics of the holy cross or consecrated wafers-it was concluded that their possession was in their imagination. This idea of placebo controls was then used in medical experiments, beginning with the Franklin commission's debunking of the psychic force of mesmerism or animal magnetism in 1784. 3 The use of the word placebo in a medical context to describe innocuous treatments to make a patient comfortable dates from at least the end of the 18th century. 4 The earlier, unsavoury connections undoubtedly led to the tainted reputation of placebos and placebo eff ects that persisted until very recently. 1 Mainstream interest in placebo eff ects only began with the widespread adoption of the randomised controlled trial (RCT) after World War II, when it was noticed that people improved-some times dramatically-in placebo control groups. 5 Soon after, in his famous proto-meta-analysis, Henry Beecher claimed that about 35% of patients responded positively to placebo treatment. 6 Beecher, however, encouraged an infl ated notion of the "powerful placebo" because he failed to distinguish the placebo response from other confounding factors. Since this time, there has been increasing interest in investigating placebo eff ects by rigorous research methods, especially in the past 10 years. In this Review, we assess whether advances in under standing of placebo mechanisms in both laboratory and clinical settings could lead to a reconsideration of placebo eff ects with implications for clinical practice.
Conceptual background
The association of placebo eff ects with RCTs has caused confusion because the response in the placebo group is not necessarily a genuine psychosocial response to the simulation of treatment. In fact, the reported response to placebo in RCTs might refl ect the natural course of disease, fl uctuations in symptoms, regression to the mean, response bias with respect to patient reporting of subjective symptoms, or other concurrent treatments. Furthermore, a traditional focus on the inert content of a placebo has led to diffi culties in defi ning and understanding placebo eff ects, 7, 8 not to mention applying them in clinical research and practice.
Search strategy and selection criteria
We searched the Cochrane Library (2001-09), Medline (1902 Medline ( -2009 ), PreMedline, and Embase ) databases for reports published in English using the search terms "placebo", "placebo eff ect", "placebo response", "nocebo", "context eff ect", "patient-therapist interaction", "expectation", and "conditioning". We mainly selected reports published in the past 10 years, but did not exclude frequently referenced and highly regarded older publications, especially those that were pertinent to the history and understanding of placebo eff ects. We also searched the reference lists of articles identifi ed by this search strategy, particularly the reference lists of systematic reviews and meta-analyses, and selected those we judged relevant, including review articles and book chapters. Reports were included if they studied or discussed the history, ethics, and mechanisms of placebo use and placebo eff ects both in experimental and clinical settings. In the case of mechanistic and clinical trials, trials were only included if they were controlled; however, rare exceptions were made for older and relevant articles in which a control group was not used.
Generally, a placebo is seen as an inert substance or procedure and the placebo eff ect (or response) is something that follows administration of a placebo. The paradox here is that if something is inert, it is by defi nition unable to elicit an eff ect. 7, 8 This defi nition can be further confused with terms such as active, 10 true, and perceived placebos, 11 which are all attempts to better understand placebo eff ects, and other terms such as context eff ects 12, 13 and meaning responses, 7 which have shifted the focus from the use of the word placebo. Nevertheless, the placebo terminology, despite its defects, is too engrained in the scientifi c literature to replace it at this time, especially in the absence of a satisfactory alternative.
To resolve these confusions and better understand placebo eff ects in clinical trials and practice, it is necessary to reconsider placebos and placebo eff ects, shifting the focus from the inert content of a placebo or sham procedure to what the placebo interventionconsisting of a simulated treatment and the surrounding clinical context-is actually doing to the patient. Accumulated evidence suggests that the placebo eff ect is a genuine psychobiological event attributable to the overall therapeutic context. 9, 14 This psychosocial context can consist of individual patient and clinician factors, and the interaction between the patient, clinician, and treatment environment. The treatment environment represents the many factors associated with a treatment context (such as the specifi c nature of the treatment and the way it is delivered) and the patient-clinician relationship, which is a term that encompasses several factors that constitute the therapeutic interaction (fi gure 1). 12 The placebo intervention is designed to simulate a therapeutic context such that the eff ect of the intervention (placebo eff ect) is attributable to the way in which this context aff ects the patient's brain, body, and behaviour. 9 When an active treatment is given, the overall response is the result of the treatment itself and the context in which it is given. Such a concept allows for progression in understanding of the many factors that make up the psychosocial context surrounding a patient and how these factors, and the mechanisms by which they operate, can be enhanced in clinical practice.
Mechanisms of placebo eff ects
Some of the mechanisms that underlie placebo eff ects are summarised in the table, showing that there is not one placebo eff ect, but many. [14] [15] [16] These mechanisms can be broadly discussed from psychological and neurobiological viewpoints.
Psychological mechanisms
From a psychological viewpoint, there are many mechanisms that contribute to placebo eff ects. These mechanisms include expectations, conditioning, learning, memory, motivation, somatic focus, reward, anxiety reduction, and meaning. 9, 39 Although there is a growing amount of research into these mechanisms, two principal mechanisms are well supported.
The fi rst mechanism involves expectancy: patients given placebo have expectations of future responses. 40 Many experiments have used simple verbal cues as modulators of expectations. 17, 33, 41 For example, a participant receiving experimentally induced pain is given a topical placebo cream in the context of two diff erent cues: the fi rst that the cream is inert and will have no eff ect and the second, that the cream is a powerful pain killer. 41 Such verbal cues have been shown to manipulate patients' expectations and mediate placebo eff ects-eg, placebo analgesic eff ects in experimental 33 and clinical pain, 42 placebo-induced changes in motor performance in Parkinson's disease, 23, 43 changes in emotions, 28 and brain responses in patients with drug addiction. 30 Furthermore, the presence of a conditioning protocol to increase expectations results in larger analgesic responses to placebo, showing that expectation can both mediate and modulate placebo eff ects, 17, 44, 45 as well as interact with other constructs such as desire and emotion. 9, 42 A second mechanism underlying placebo eff ects involves classical conditioning. 46 Repeated associations between a neutral stimulus and an active drug (unconditioned stimulus) can result in the ability of the neutral stimulus by itself to elicit a response characteristic of the unconditioned stimulus. Classical conditioning mechanisms have been shown in both animal 34, 47, 48 and human studies, 35, 36, 44, 45 although it has been diffi cult to exclude any cognitive component (such as expectation) in human beings. 49, 50 Despite this issue, conditioning mechanisms in human beings are substantiated by the fact that placebo eff ects are higher in magnitude after a conditioning protocol (even if an expectation mechanism is present). 17 Additionally, conditioning mechanisms mediate placebo-induced changes in unconscious physiological processes such as hormone secretion 36 and immune responses. 35 The interaction between expectation and conditioning mechanisms remains an area for further research, which might be particularly relevant to exploring the clinical implications of these mechanisms. Although classical conditioning, manifesting an automatic unconscious mechanism, exists in human beings, it can also be regarded as a complex process consisting of cognitive components and derived from previous experience of either positive or negative therapeutic outcomes. 51 Accordingly, conditioning and expectation are certainly entangled in the occurrence of placebo eff ects in clinical practice. The most reasonable interpretation of recent publications is that conditioning follows expectation and is dependent on the success of the fi rst encounter. This notion leads to the possibility that the fi rst encounter is crucial for the development of subsequent robust placebo responses: the higher the expectation, the greater the placebo eff ect, and potentially the greater the conditioning eff ects associated with future drug intake.
In addition to classical conditioning, other learning processes such as past experiences and social observation mediate placebo eff ects. 52 For example, participants who observed a demonstrator simulating responsiveness to a therapy had placebo analgesic responses that were similar in magnitude to those in patients who received a classical conditioning procedure. 53 
Neurobiological mechanisms
Looking at placebo mechanisms from the neurobiological viewpoint further emphasises that there are several placebo eff ects. Placebo eff ects can occur in diff erent physiological systems in healthy volunteers and in patients with many diff erent clinical conditions (fi gure 2).
Most research into the neurobiology of placebo responsiveness has addressed placebo analgesia; accordingly, the neurobiology of placebo eff ects is usually considered in terms of opioid and non-opioid mechanisms. 54, 55 Several studies have shown that placebo eff ects can be completely 18, 19, 56 or partly reversed 57 by the opioid antagonist naloxone, supporting the involvement of endogenous opioids in some placebo analgesic eff ects. 58 Furthermore, placebo analgesic eff ects are likely to be inhibited by the peptide cholecystokinin, 19 since such eff ects are potentiated in patients treated with cholecystokinin antagonist. 59, 60 Several studies have shown that placebo eff ects can occur at specifi c body regions. 33, 41, 61 This body-region specifi city is reversed by naloxone, 33 suggesting that analgesic responses to placebo involve highly specifi c endogenous opioid release, rather than a more generalised opioid release (such as increased opioid concentration in the cerebrospinal fl uid). 62 These results have been substantiated and extended by brain imaging techniques such as PET 63, 64 and functional MRI. [65] [66] [67] In one PET study, brain changes in response to placebo were reported to be similar to changes seen after treatment with opioid drug. 68 Opioid-mediated placebo responses also extend beyond pain pathways. Some studies have shown that placebo-induced respiratory depression (a conditioned placebo side-eff ect) 69 and decreased heart rate and β-adrenergic activity 32 can be reversed by naloxone.
Many placebo eff ects are mediated by non-opioid mechanisms, such as the release of diff erent neurotransmitters and neuromodulators. In one study, the placebo response in participants who had previous conditioning with an opioid drug was reversed by naloxone; however, there was no reversal in those who had conditioning with a non-opioid drug. 17 Therefore, completely diff erent placebo mechanisms can be produced depending on the drug used in the conditioning protocol.
Although other medical disorders have been investigated from a neurobiological perspective, the placebo mechanisms in these conditions are little understood compared with those for pain and analgesia. For example, in patients with Parkinson's disease, administration of placebo led to dopamine release in the striatum 23, 70 and resulted in changes in basal ganglia and thalamic neuron fi ring. 24, 25 Studies have also shown changes in metabolic activity in the brain after administration of placebo in patients with depression 26 and after manipulation of expectations in patients with drug addiction. 30 
Mechanisms

Pain
Activation of endogenous opioids and dopamine (placebo); activation of cholecystokinin and deactivation of dopamine (nocebo) [17] [18] [19] [20] [21] [22] Parkinson's disease Activation of dopamine in the striatum and changes in activity of neurons in basal ganglia and thalamus [23] [24] [25] Depression Changes of electrical and metabolic activity in diff erent brain regions (eg, ventral striatum) 26, 27 Anxiety Changes in activity of the anterior cingulated and orbitofrontal cortices; genetic variants of serotonin transporter and tryptophan hydroxylase 2 28, 29 Addiction Changes of metabolic activity in diff erent brain regions 30 Autonomic responses to deep brain stimulation
Change of neuronal excitability in limbic regions 31 Cardiovascular system Reduction of β-adrenergic activity of heart 32 Respiratory system Conditioning of opioid receptors in the respiratory centres 33 Immune system Conditioning of some immune mediators (eg, interleukin 2, interferon γ, lymphocytes) 34, 35 Endocrine system Conditioning of some hormones (eg, growth hormone, cortisol) 36 Physical performance Activation of endogenous opioids and increased muscle work 37, 38 Alzheimer's disease Prefrontal executive control and functional connectivity of prefrontal areas 21 Less research has been concerned with the nocebo eff ect, an occurrence that is opposite to the placebo eff ect. The reason for the paucity of data is mainly because of ethical limitations, since nocebo administration involves the induction of negative expectations. Cholecystokinin has a key role in nocebo hyperalgesia, which occurs through anticipatory anxiety mechanisms. 20, 21, 37 De activation of dopamine release has also been found in the nucleus accumbens during nocebo hyperalgesia, 22 which suggests the involvement of diff erent neuro transmitters. Furthermore, a neuroimaging study has shown that nocebo aff ects brain activation diff erently from placebo, including in the hippocampus and regions involved with anticipatory anxiety.
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Implications for clinical practice
Understanding how placebo eff ects work clinically in relevant patient populations over time has not kept pace with the recent research into mechanisms of placebo eff ects, which has mainly involved laboratory experiments done over short durations with healthy participants. In the case of clinical populations, the study of long-term placebo responsiveness has been limited to RCTs. However, these studies rarely included groups of participants receiving no treatment to control for natural history and regression to the mean, making it diffi cult to discern a genuine placebo eff ect. Several meta-analyses have attempted to address the presence and magnitude of placebo eff ects in RCTs, including some studies in which no-treatment control groups were used. These analyses concluded that placebo eff ects are small and limited to subjective outcomes when placebos are used as a control condition in RCTs. [72] [73] [74] However, placebo eff ects are much larger in studies that investigate placebo mechanisms. 75, 76 This fi nding is not at all surprising given that the mechanistic experiments use controlled manipulations of verbal instructions and context that might be more representative of normal clinical practice than a clinical trial setting. It is therefore important to bridge this gap by looking at placebo research from basic science, clinical trial, and ethical perspectives in an attempt to better understand how placebo eff ects operate in the clinical setting.
A single-blind RCT in 262 patients with irritable bowel syndrome investigated whether placebo eff ects can be disaggregated into two main components (placebo ritual alone and placebo ritual plus supportive patient-clinician relationship) and then progressively combined to produce clinically signifi cant improvements compared with no treatment. 77 The placebo ritual consisted of a validated placebo acupuncture device, which was used in both treatment groups. 78 Instead of penetrating the skin, the needle retracts into the needle handle. The supportive patient-clinician relationship, used only in one group, was prospectively scripted and consisted of attention, warmth, confi dence, and thoughtful silence. At the 3-week outcome, adequate relief on a validated measure for irritable bowel syndrome was reported by 62% of participants in the placebo ritual plus supportive care group, 44% in the placebo ritual alone group, and 28% in the no-treatment group (p<0·001). The results were similar with three other validated measures for irritable bowel syndrome used in the study. The eff ect size of 62% adequate relief was similar to the improvement seen in patients treated with alosetron in RCTs of irritable bowel syndrome. 79 Outcomes were similar after an additional 3 weeks of follow-up. In addition to showing that genuine placebo eff ects can be statistically and clinically signifi cant over time in clinical populations, this trial showed that placebo eff ects can be incrementally added in a manner resembling a graded dose escalation of component factors. In a separate analysis of the study, patient extroversion, agreeableness, and openness to experience were found to be associated with placebo responses in the placebo ritual plus supportive care group but not in . These receptors are the same to which diff erent drugs bind, suggesting that psychosocial factors are capable of modulating the action of drugs. This interference has implications for our understanding of drug action: when a drug is prescribed, the very act of giving it to a patient (ie, the psychosocial context) might aff ect the system and change the response to the drug. Reproduced with permission from reference 39. IFNγ=interferon γ. IL2=interleukin 2. CCK=cholecystokinin.
the placebo ritual alone group. 80 The investigators also reported signifi cant diff erences in outcomes between practitioners. Future integration of such study designs in RCTs with mechanistic laboratory work will allow for better understanding of these placebo mechanisms and how they can be augmented in clinical practice.
Several RCTs have examined whether diff erent methods for delivery of placebo produce diff erent eff ects. 81 The largest such study, in 270 patients with chronic arm pain caused by repetitive use, compared a sham device (placebo acupuncture) with an inert oral pill. 82 At 2 weeks of treatment, patients assigned to placebo pills had greater improvement in ability to function (mainly related to less disturbed sleep because of pain) than did patients assigned to sham acupuncture (p<0·05); however, pain did not diff er between groups. At the end of the study (6 weeks), patients assigned to sham acupuncture had a signifi cant reduction in pain compared with those in the placebo pill group (p<0·001). Depending on the complaint and the length of time that placebo was received, diff erent placebos had diff erent eff ects. Not all medical rituals are the same: placebo pills are better for sleep and sham needles are better for pain. Nocebo eff ects also diff ered between treatment delivery groups. Patients in the placebo pill group were told they might have the adverse eff ects (eg, drowsiness) of a medication (amitriptyline) and the sham acupuncture group was informed about the side-eff ects of acupuncture. Although 30% of people in both placebo groups reported adverse eff ects, the type of eff ects diff ered between groups and mimicked the information provided during the informed consent process.
Some commentators have suggested that alternative therapies with elaborate procedures and distinct environmental cues might have pronounced and clinically signifi cant placebo eff ects. 83, 84 Recent RCTs of acupuncture, although not designed to study placebo eff ects, have provided results that lend support to this hypothesis. A series of large trials in Germany compared acupuncture done according to traditional Chinese medicine (verum acupuncture), sham acupuncture (superfi cial needling at non-acupuncture points), and either no-treatment or usual clinical care. Conditions studied included migraine, 85 tension headaches, 86 chronic low back pain, 87, 88 and osteoarthritis of the knee. 89 Generally across the various trials, outcomes did not diff er between verum and sham acupuncture groups; however, participants in both of these groups had substantially greater symptom improvement than did those in the no-treatment and usual clinical care control groups. 90 Linde and colleagues 91 reported that in four of these RCTs (n=864), patient's expectation of pain relief was the most robust predictor of effi cacy of acupuncture treatment, irrespective of the group assignment to genuine or sham treatment. The eff ect of positive expectation on outcome lasted for 1 year. These results therefore accord with the hypothesis that acupuncture works by means of a placebo eff ect. A more recent study in 640 patients with chronic low back pain showed that participants assigned to 8 weeks of toothpick simulation sham acupuncture plus usual care had clinically meaningful improvements in outcomes compared with those assigned to usual clinical care alone, and such eff ects also lasted for 1 year. 92 This study however did not fi nd a correlation between measured expectation and outcomes. 93 Some of the clearest evidence supporting the involvement of placebo eff ects in clinical care comes from trials with an open-hidden study design (fi gure 3). In this experimental approach, a treatment is given in a routine manner (open treatment), in which the psychosocial context surrounding treatment administration is present, and in a hidden manner, in which the treatment is given without the patient's knowledge. In the case of a drug intervention, the open treatment mimics normal clinical care; the clinician injects a drug in full view of the patient with verbal and contextual interactions. For the hidden treatment, the drug is infused by a computer pump in the absence of the clinician and the therapeutic context. Patients receiving hidden treatment are aware that at some stage they will receive a drug but they do not experience the expectation component or other contextual factors surrounding the The non-specifi c eff ect might come from the knowledge that a treatment is being given. The eff ectiveness of the active treatment can be assessed either by eliminating its specifi c eff ect (placebo study) or by eliminating the non-specifi c eff ects (hidden treatment). Reproduced from reference 94.
treatment. Because the hidden administration removes the psychosocial context of treatment, the placebo component is defi ned as the diff erence in outcome between open and hidden treatments, although no placebo is given.
94,95
The open-hidden study design has been used in several clinical settings. Hidden treatment with widely used painkillers (morphine, buprenorphine, tramadol, ketorolac, metamizol) has been shown to be markedly less eff ective in reducing pain than has open treatment. 94, 96, 97 This fi nding was seen in both healthy volunteers receiving experimentally induced pain (pain ratings were higher in the hidden treatment group than in the open treatment group) and in patients with postoperative pain (the dose needed to reduce pain by 50% was much higher in the hidden treatment group than in the open treatment group). 96 Similar diff erences between open and hidden treatment groups have been reported after drug treatment in patients with anxiety and after deep brain stimulation in patients with Parkinson's disease. 31, 97 Slightly diff erent methods have been used in patients with drug addiction; the absence of an expectation component in patients given stimulant drug treatment resulted in reduced regional brain glucose metabolism and verbal reports of effi cacy. 30 Thus, the overall outcome of a treatment combines the specifi c pharmacological or physiological action of the treatment and the psychosocial context in which it is delivered. The psychosocial context represents the placebo component, which is based on patient expectations.
The open-hidden study design has provided a means of exploring the interaction between placebo eff ects and responses to active treatments. This analysis has not been possible in standard RCTs designed to assess treatment effi cacy, since they only compare the response to placebo with the response to the index intervention without providing an understanding of the interaction between the two. For example, fi ndings from a clinical trial done in 1995 showed that the cholecystokinin antagonist proglumide was more eff ective in reducing intensity of postoperative pain than was placebo, which in turn was more eff ective than no treatment. 59 According to methods of analysis used in classic clinical trials, these results would suggest that proglumide is a good analgesic drug that acts on pain pathways, whereas placebo reduces pain by activating placebo analgesic mechanisms (through expectation pathways). However, this conclusion is erroneous, since a hidden injection of proglumide had no analgesic eff ect. If the drug is an eff ective modulator of pain pathways, such a diff erence between open and hidden treatment would not be seen. In this instance, the drug achieves a response by interacting with and enhancing placebo mechanisms (expectation pathways), not by acting on pain pathways, and therefore is only eff ective when combined with the placebo mechanisms inherent in the clinical encounter.
Placebo mechanisms can interact with drug treatments, even if no placebo is given, since every treatment is given in a therapeutic context that has potential to activate and modulate placebo mechanisms, many of which can act on similar biochemical pathways to the actual drug (fi gure 2).
A short-term experimental trial done in 2001 has advanced our understanding of the clinical implications of modulating placebo eff ects in routine clinical care. In this trial, which assessed postoperative pain over several days, patients were given intravenous saline (placebo) as a background infusion in addition to routine analgesic treatment (buprenorphine on request). 98 One group of patients was told that the basal infusion was a rehydrating solution (natural history control group) and another group was told that it was a powerful painkiller (maximum placebo context). Overall intake of buprenorphine was monitored throughout the trial. The clear diff erences in the context (mainly expectation of benefi t) of the basal infusion resulted in substantial diff erences in drug intake. The group who believed the solution was assisting in analgesia took 33% less buprenorphine for the same pain control than did those in the natural history control group, showing an important clinical eff ect and the potential for use of placebo eff ects in conjunction with an active treatment to reduce overall drug intake. A third group were told that "the solution may or may not be a powerful painkiller", representing classic double-blind treatment used in placebo-controlled trials. In this group, patients took 20% less buprenorphine than did controls.
Similar modulations in short-term placebo eff ects have been reported in more recent studies in patients with irritable bowel syndrome. 42, 99 In these studies, patients were exposed to a painful stimulus (rectal distention bal loon) under two conditions: local anaesthetic and placebo. In one study, patients were told that they "may receive an active or a placebo agent", 99 whereas in the second, they were told that "the agent you have been given is known to signifi cantly reduce pain in some patients". 42 The subtle changes in expectations aff ected the magnitude of placebo responses, with larger placebo responses reported in the second trial, which had more defi nite instructions.
Clinicians' expectations also seem to aff ect placebo responses. In a small, double-blind trial done in 1985, patients with postoperative dental pain were divided into two groups and told that they could receive a drug which would increase their pain (naloxone), decrease their pain (fentanyl), or have no eff ect (placebo). 100 By contrast, the clinicians were told that in one of the groups, there was no chance of receiving an active analgesic drug, and to this extent it was the clinicians who were manipulated and not the patients. The placebo response was substantially lower in the group that clinicians believed would receive no analgesic treatment. The double-blind nature of the study suggests that alterations in clinicians' beliefs might alter the therapeutic context (and placebo eff ect) in subtle ways, since patients were not aware of the information given to the clinicians.
Loss of placebo mechanisms can have important clinical ramifi cations. For example, an open-hidden study in patients with Alzheimer's disease showed that the placebo component (diff erence between open and hidden treatments) was correlated with cognitive status and functional connectivity between brain regions. 101 Reductions in both cognitive status and functional connectivity correlated with reduced placebo mechanisms and reduced overall analgesic eff ect, so much so that an increase in dose was needed for the same level of analgesia. This fi nding shows the importance of not only attempting to increase placebo components of treatments, but also of assessing situations in which loss of placebo mechanisms might necessitate an increased therapeutic dose.
Ethical principles of enhancing placebo eff ects in clinical care
Any ethical assessment of eff orts to promote placebo eff ects in clinical practice fi rst requires knowledge as to the clinical relevance and importance of placebo eff ects. The evidence reviewed here outlines the potential for placebo interventions and the therapeutic context to promote clinically important symptomatic relief. Nevertheless, more studies of placebo eff ects in specifi c clinical settings are needed before use of treatments with the primary aim of promoting placebo responses can be recommended as evidence-based practice.
A second important ethical consideration relates to whether and how placebo eff ects can be promoted without deception. Since placebo eff ects are inherent in routine clinical care, and the psychosocial context surrounding the patient (including the patient-clinician interaction and the therapeutic procedure) can be enhanced to improve these placebo eff ects, it is ethically acceptable, not to mention clinically relevant, to provide a supportive clinical encounter that relieves anxiety and promotes positive expectations along with honest disclosure of the expected benefi ts of a medically indicated treatment. Therefore, routine conscious attempts to identify and exploit features of the clinical encounter to augment placebo eff ects represent one ethical (non-deceptive) means of applying the understanding of placebo mechanisms to improve clinical outcomes.
Whether it is ethical to recommend a treatment primarily to produce a placebo eff ect is a more complicated and controversial question. Most studies of the placebo eff ect have used deception in the administration of inert placebos as a key element of experimental design. Whereas the use of deception in research poses its own ethical issues, 102 the problem of deception in clinical practice raises even stronger concerns. To recommend or give a placebo intervention deceptively as a treatment with specifi c effi cacy for a patient's condition violates informed consent and threatens the trust that is central to clinical practice. 103 Recent data suggest that prescriptions of sugar pills and saline injections are rare, 104, 105 but that clinicians often prescribe various active treatments with the main intent of promoting a placebo response or complying with the wishes of the patient. The available evidence suggests that the practice of disclosure to patients regarding such placebo treatments is deceptive or at least not suffi ciently transparent.
Can a recommendation for a treatment intended to promote the placebo eff ect be made without deception and also without undermining its therapeutic potential? Consider, for example, the case of a clinician who recommends acupuncture treatment for a patient with chronic low back pain who has not been helped by standard medical therapy. Aware of the results of the recent acupuncture trials, this clinician thinks that acupuncture might work by promoting a placebo response. The clinician might provide the following disclosure to the patient: "I recommend that you try acupuncture. Several large studies have shown that traditional acupuncture is not better than fake acupuncture treatment, but that both of these produce substantially greater symptom improvement in patients with chronic low back pain compared with those patients who receive no treatment or conventional medical therapy. Although the specifi c type of needling does not seem to make any diff erence, it is possible that acupuncture works by a psychological mechanism that promotes self-healing, known as the placebo eff ect". At face value, this disclosure seems honest. A patient who received this disclosure and subsequently got better after undergoing acupuncture might nonetheless develop a false belief about why it worked. This does not mean, however, that the patient has been deceived by his or her clinician.
Can it be ethical for clinicians to prescribe inert placebos with a disclosure that the treatment being given "has been shown to be eff ective by altering pain transmission in similar ways to other treatments"? As is the case with most studies of the placebo eff ect, 102 an element of deception is involved. In this case, the element of deception relates to a lack of full disclosure of the content of the placebo and the complete reason for why it is being given-ie, not only to modulate pain transmission but to do so through a placebo eff ect. Therefore, as with acupuncture, completely eliminating deception would require additional disclosure that the placebo had no active drug in it and would be working through psychological mechanisms that promote selfhealing. How such disclosure might aff ect placebo responses is unknown, and apart from two small trials in patients with various mild psychiatric symptoms (and without a no-treatment control group), 106, 107 no research has addressed this important question. It is therefore important that clinicians who are recommending treatments for the primary aim of enhancing placebo eff ects are aware of the ethical implications of diff erent types of disclosure and the potential for deception. Clinically focused research is needed to explore nondeceptive techniques for prescribing treatments aimed at promoting placebo eff ects.
Conclusions
Laboratory evidence supports the existence of several placebo mechanisms and placebo eff ects in both healthy volunteers and patients with a variety of medical conditions. Furthermore, clinically relevant evidence shows that placebo eff ects can have meaningful therapeutic eff ects, because of their long magnitude and duration, in diff erent patient populations. Although substantial progress has been made in understanding placebo eff ects, much laboratory and translational clinical trial research remains to be done, with the ultimate aim of harnessing placebo eff ects to improve patient care.
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